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Abstract
Introduction: High prion protein (PrP) levels are associated with breast, colon and gastric cancer resistance to
treatment and with a poor prognosis for the patients. However, little is known about the underlying molecular
mechanism(s) regulating human PrP gene (PRNP) expression in cancers. Because endoplasmic reticulum (ER) stress
is associated with solid tumors, we investigated a possible regulation of PRNP gene expression by ER stress.
Methods: Published microarray databases of breast cancer tissues and breast carcinoma cell lines were analyzed
for PrP mRNA and ER stress marker immunoglobulin heavy chain binding protein (BiP) levels. Breast cancer tissue
microarrays (TMA) were immunostained for BiP and PrP. Breast carcinoma MCF-7, MDA-MB-231, HS578T and
HCC1500 cells were treated with three different ER stressors - Brefeldin A, Tunicamycin, Thapsigargin - and levels of
PrP mRNA or protein assessed by RT-PCR and Western blot analyses. A human PRNP promoter-luciferase reporter
was used to assess transcriptional activation by ER stressors. Site-directed mutagenesis identified the ER stress
response elements (ERSE). Chromatin immunoprecipitation (ChIP) analyses were done to identify the ER stress-
mediated transcriptional regulators. The role of cleaved activating transcription factor 6a (ΔATF6a) and spliced
X-box protein-1 (sXBP1) in PRNP gene expression was assessed with over-expression or silencing techniques. The
role of PrP protection against ER stress was assessed with PrP siRNA and by using Prnp null cell lines.
Results: We find that mRNA levels of BiP correlated with PrP transcript levels in breast cancer tissues and breast
carcinoma cell lines. PrP mRNA levels were enriched in the basal subtype and were associated with poor prognosis
in breast cancer patients. Higher PrP and BiP levels correlated with increasing tumor grade in TMA. ER stress was a
positive regulator of PRNP gene transcription in MCF-7 cells and luciferase reporter assays identified one ER stress
response element (ERSE) conserved among primates and rodents and three primate-specific ERSEs that regulated
PRNP gene expression. Among the various transactivators of the ER stress-regulated unfolded protein response
(UPR), ATF6a and XBP1 transactivated PRNP gene expression, but the ability of these varied in different cell types.
Functionally, PrP delayed ER stress-induced cell death.
Conclusions: These results establish PRNP as a novel ER stress-regulated gene that could increase survival in breast
cancers.
Introduction
Growing evidence indicates that prion protein (PrP) is
associated with cellular survival. PrP confers neuroprotec-
tion against serum-deprivation [1], Bax protein [2-7],
oxidative stress [8], ischemia [9] and PrP mutants or prion-
like protein Doppel [10,11]. The anti-cell death activity of
PrP also occurs in peripheral cell types and has been asso-
ciated with several types of cancer. High levels of PrP
induce resistance of MCF-7 breast carcinoma cells to
tumor necrosis factor alpha, Tumor Necrosis Factor-
Alpha-Related Apoptosis-Inducing Ligand (TRAIL)-, and
Bax-mediated apoptosis [4,12,13]. In estrogen receptor
negative breast tumors, PrP expression is associated with
chemotherapy resistance [14]. Non-glycosylated and
unprocessed non-glycophosphatidyl inositol anchored PrP
is expressed in human pancreatic ductal adenocarcinoma
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and melanoma cell lines and confers increased prolifera-
tion, invasiveness and growth to these cells by interacting
with the actin-regulating filamin A protein [15,16]. PrP is
also over-expressed in gastric cancers [17], associated with
resistance to chemotherapy and poor prognosis [18], and
promotes proliferation, invasion and metastasis [19,20].
The induction of PrP in gastric cancer is related to hypoxia
[21], and PrP is associated with increased activation of Akt,
increased levels of Bcl-2, decreased levels of Bax and a dys-
regulation of calcium-related genes [22,23]. PrP is also
implicated in colon cancer. PrP levels are higher in the
most aggressive colon cancer cell lines [24] and in higher-
grade human colorectal carcinomas [25]. Antibodies
against PrP decrease cellular proliferation of colon carci-
noma HCT116 cells and also decrease xenograft tumor
growth in combination with irinotecan chemotherapy [24].
Furthermore, PRNP gene expression correlates with color-
ectal cancer recurrence [26].
Preliminary evidence suggests that endoplasmic reticu-
lum (ER) stress may also regulate PRNP gene expression in
breast cancer cells. Brefeldin A (BFA) significantly increases
PrP levels in breast carcinoma MCF-7 cells [27]. Two other
ER stress-inducing compounds, bisphenol A or misfolded
surfactant protein C, increase PrP levels in mouse testicular
Sertoli TTE3 and human embryonic kidney 293 (HEK293)
cells [28,29]. ER stress initially induces a survival response
via the unfolded protein response (UPR); however, pro-
longed activation leads to apoptosis [30]. The UPR triggers
protein refolding [31], attenuation of protein translation
[32] and degradation of misfolded proteins [33] via three
transmembrane proteins; the activating transcription factor
6a (ATF6a), the double-stranded RNA-activated protein
kinase-like ER kinase (PERK) and the inositol-requiring
enzyme 1a (IRE1a). Under ER stress, ATF6a translocates
to the Golgi apparatus and is processed by site-1 and site-2
proteases to generate cytosolic cleaved ATF6a (ΔATF6a).
ΔATF6a translocates to the nucleus and activates tran-
scription of ER chaperones, XBP1 and the CCAAT/enhan-
cer-binding protein homologous protein (CHOP) [34,35].
IRE1a cleaves the mRNA of XBP1 generating a spliced
variant (sXBP1) that acts as a transcriptional activator of
chaperones and genes involved in protein degradation [36].
PERK phosphorylates the eukaryotic initiation factor 2a
(eIF2a) and leads to a general decrease in protein transla-
tion. Phosphorylation of eIF2a also causes a preferential
translation of the activating transcription factor 4 (ATF4)
that induces genes mainly involved in amino acid metabo-
lism and stress response [37]. ΔATF6a and sXBP1 recog-
nize an ERSE defined in glucose-regulated genes by a
consensus CCAAT-N9-CCACG sequence [35]. In addition,
an ATTGG-N-CCACG ERSE-II motif also responds to
ER stress [38]. The ERSE motifs can accommodate nucleo-
tide substitutions and operate in a bi-directional manner
[35,38-43].
Given that ER stress-mediated activation of the UPR
occurs in cancer tissues and cell lines [44,45], we investi-
gated its effect on PRNP gene expression in breast cancer.
We found that high mRNA levels of the ER stress marker,
immunoglobulin heavy chain binding protein (BiP), corre-
lated with high levels of PrP mRNA in breast cancer tissues
and cell lines, both at the RNA and protein level. The high
PrP mRNA levels were associated with a poorer prognosis
and with the acquisition of a basal phenotype, which is
associated with poor patient survival. We then explored the
underlying molecular pathway by which ER stress increased
PRNP gene expression in the breast carcinoma MCF-7 cell
line. Our results showed that ER stress increased endogen-
ous PrP levels through ERSE motifs of the human PRNP
promoter. Among the transactivators induced by the three
UPR pathways, ATF6a and sXBP1 were both capable of
transactivating PRNP gene expression. Silencing PrP exa-
cerbated ER stress-induced apoptosis in the MCF-7 and
MDA-MB-231 cell lines. These results establish PRNP as a
novel ER stress-regulated gene and implicate PrP as a pro-
survival factor in breast cancer cell lines.
Material and methods
Tissue microarrays and immunohistochemistry
All human tissue used for research was obtained by ethical
consent of patients [46] and protocol was approved from
the Centre Hospitalier de l’Université de Montréal Research
Ethics Committee under Canadian Institutes of Health
Research (CIHR) guidance rules and in compliance with
the Helsinki Declaration. Tissue microarrays (TMAs) were
composed of formalin-fixed, paraffin-embedded breast can-
cer biopsies collected at the Centre Hospitalier de l’Univer-
sité de Montréal. After re-hydration of the TMA, antigen
retrieval was performed by heating the slides in Antigen
Unmasking Solution (Vector Laboratories, Burlingame, CA,
USA) with a steam oven. Immunohistochemical staining
was performed on a Dako Autostainer Plus (Dako, Burling-
ton, ON, Canada). Briefly, Peroxidase Block solution and
Protein Block solution was applied on slides before the
anti-PrP (1:500, 3F4) or anti-BiP (1:500, Cell Signaling
Technologies, Danvers, MA, USA, #3177) antibodies. The
3F4 epitope-spanning peptide PrP106-114 (Anaspec, Fre-
mont, CA, USA) or BiP blocking peptide (Cell Signaling)
were used to adsorb their respective antibody immunoreac-
tivity. Slides were developed with the Envision Flex DAB
Chromagen system (Dako, Burlington, ON, Canada) and
counterstained with hematoxylin. Slides were mounted in
permount and scanned with a Mirax Scan 150 BF/FL Digi-
tizer (Carl Zeiss, Toronto, ON, Canada).
Cell culture and treatments
MCF-7 cells (ATCC, Manassas, VA, USA) were seeded at
1 × 106 cells per 35 mm well and treated with 5 μg/mL
BFA, 3.25 μg/mL Thps, 2.5 μg/mL TM or their vehicle
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(Biomol Research Laboratories, Plymouth Meeting, PA,
USA) in complete cell culture media and in the absence
or presence of 1 μg/mL actinomycin D or 20 μg/mL
cycloheximide (Sigma-Aldrich, Oakville, ON, Canada) for
the indicated times. Serum deprivation of MCF-7 cells
was done for 6 and 18 hours. Basal cell lines MDA-MB-
231 (ATCC) and HS578T (ATCC) were seeded at 0.8 ×
106 per 35 mm well and treated for 20 h with 10 μM
4-Phenyl-Butyric Acid (4-PBA). HCC1500 cells were
obtained from ATCC and were cultured at 1 × 106 cells
per 35 mm well in RPMI and 10% FBS. MDA-MB-231,
HS578T and HCC1500 cells were all treated with 5 μg/mL
of BFA, Thps or TM.
Protein extraction and western blot analyses
Cells were lysed on ice in lysis buffer (150 mM NaCl,
2 mM Ethylenediaminetetraacetic acid (EDTA), 0.5%
Triton X-100, 0.5% sodium deoxycholate, 50 mM Tris-
HCl, pH 7.5, 38 μg/mL 4-(2-Aminoethyl) benzenesulfo-
nyl fluoride (AEBSF), 0.5 μg/mL leupeptin, 0.1 μg/mL
pepstatin, 0.1 μg/mL N-a-p-tosyl-L-lysine chloromethyl
ketone hydrochloride, 4 mM sodium orthovanadate,
20 mM sodium fluoride). Protein concentration was
determined with the BCA Protein Assay Reagents (Fisher
Scientific, Toronto, ON, Canada). Proteins were precipi-
tated in methanol, dried and solubilized in Laemmli sample
buffer before being boiled, migrated on SDS-PAGE gel and
transferred to PVDF membranes. Membranes were blotted
for PrP (3F4 1:2,000), b-actin (AC-15 1:5,000, Sigma),
CHOP (B-3 1:1,000, Santa Cruz Biotechnology, Santa Cruz,
CA, USA), BiP (H-129 1:250, Santa Cruz Biotechnology),
ATF6a (1:500, Imgenex, San Diego, CA, USA), eIF2a
(1:500, Cell Signaling), phosphorylated eIF2a (peIF2aSer51
1:500, Cell Signaling), XBP1 (M-186 1:200, Santa Cruz Bio-
technology), Bax (2D2 or N-20 1:2,000 or 1:3,000, Sigma),
Bim (Y-36 1:5,000, Epitomics, Burlingame, CA, USA) and
Bcl-2 (100 1:250, Santa Cruz Biotechnology). Immunoreac-
tivity was revealed with horseradish peroxidase (HRP) or
alkaline phosphatase secondary antibodies (1:5,000, GE
Healthcare Bio-Sciences, Piscataway, NJ, USA or Jackson
ImmunoResearch Laboratories, West Grove, PA, USA) and
ECL or NBT/BCIP (GE Healthcare, EMD Millipore, Biller-
ica, MA, USA, or Promega, Madison, WI, USA).
RT-PCR analyses of PrP, spliced XBP1, ATF6a and b-actin
mRNA
Total RNA was isolated from MCF-7 with the TRIzol
reagent according to the manufacturer’s protocol (Invitro-
gen Life Technologies, Burlington, ON, Canada). Reverse
transcription was accomplished with avian myeloblastosis
virus (AMV) reverse transcriptase (Roche Diagnostics,
Laval, QC, Canada) and Oligo dT12-18 (GE Healthcare)
while the PCR amplification were done with FideliTaq
DNA polymerase (USB Corporation, Cleveland, OH,







ATF6a-For 5’ TGGGGGAGTCACACAGCTCCC 3’,
ATF6a-Rev 5’ AGCTGCCGCTTCAGTGTTCCA 3’. The
PCR conditions were 1 cycle of 5 minutes at 95°C, 25
cycles of 30 sec at 95°C, 1 minute at 50°C and 1 minute at
68°C, followed by 1 cycle of 5 minutes at 68°C.
Luciferase assays
The pGL-538 and pGL-214 human PrP promoter con-
structs were kindly provided by Dr. J. Collinge (MRC
Prion Unit, London, UK) and contain 538 or 214 nucleo-
tides upstream of the start site and 125 nucleotides of
exon I into the pGL2-Basic vector [48]. The pRL-TK vec-
tor was obtained from Promega (Madison). Point muta-
tions in pGL-538 were performed using QuikChange Site-
Directed Mutagenesis (Agilent Technologies, Santa Clara,
CA, USA). The following forward primers were used to
produce point mutations in ERSE-like 5’-AAGAT-
GATTTTTACAGTCAATGAGATCTAG AAGGGAGC-
GATGGCACCCGCAGG-3’, in ERSEa 5’-CGGCCCTG
CTTGGCAGCGCGATCGACTTTAACTTAAACCTC
GGC-3’, in ERSE-II 5’-GCGCGGCAATTGGTCATATG
GCCGACCTCCGCCCGCG-3’ and in ERSEb 5’-GCGG
CAATTGGTCCCCGCATATGTCTCCGCCCGCGAG
CGCCG-3’. The generated mutants were verified by
restriction enzyme digestion because the mutations intro-
duced a PvuI site in the ERSEa mutant, XbaI and BglII
sites in the ERSE-like mutant and NdeI site in the ERSE-II
and ERSEb mutants. HEK293T cells (ATCC) seeded at 0.6
× 106 cells/35 mm well were transfected or co-transfected
with 4 μg of pGL-214, pGL-538 or mutated pGL-538 and
0.35 μg of pRL-TK in Lipofectamine™ 2000 reagent (Invi-
trogen). ER stressors or the DMSO control was added for
6 hrs, 24 hrs after the transfection. Proteins were recuper-
ated as recommended in the Dual-Luciferase Reporter
Assay System (Promega). Firefly luciferase and Renilla
luciferase activities were measured and expressed as the
relative luminescence units (RLU) corresponding to the
ratio of the firefly luciferase activity over the Renilla luci-
ferase activity per μg of proteins. Data were normalized to
luciferase activity levels obtained from wild type PRNP
promoter.
Overexpression or silencing of proteins
Co-transfections of pGL-538 (400 ng/24-well) and 400
ng/24-well pCGN-IRES-EGFP, pCGN-HA-splicedXBP1-
IRES-EGFP (both kindly provided by Dr R. Kaufman, U.
Michigan), or pCGN-ATF6a (1-373) (Addgene plasmid
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27173) [49] with the 75 ng/24-well pRL-TK vector were
done with Lipofectamine™ 2000 (Invitrogen) in
HEK293 cells for 24 hrs before assessing Firefly and
Renilla luciferase with the Dual-Luciferase Reporter
Assay System (Invitrogen). Both XBP1 and ATF6a up-
regulated the Renilla luciferase promoter so the Firefly
luciferase data were expressed relative to the Renilla
luciferase of pCGN-EGFP and pRL-TK transfected cells.
RT-PCR was conducted to confirm the over-expression
of ATF6a and XBP1. For silencing of ATF6a and XBP1,
HEK293 cells were co-transfected with 75 ng/24-well of
pRL-TK, 800 ng/24-well of pGL-538, and 200 nM siRNAs
against human ATF6a (siATF6a) from Santa Cruz Bio-
technology (pool of three target specific siRNAs: sc-37699)
and from Dharmacon (Dharmacon, Lafayette, CO, USA)
(one siRNA: On-TARGETplus human ATF6a (22926)
siRNA) or human XBP1 siRNAs from Santa Cruz Biotech-
nology (pool of three target specific siRNAs: sc-38627) and
Dharmacon (one siRNA: On-TARGETplus human XBP1
(7494) siRNA). The si Control (siCtl) was a scrambled
siRNA from Santa Cruz Biotechnology (sc-37007) and all
transfections were done with Lipofectamine™ 2000. The
siRNAs were transfected for 24 hrs and then ER stressors
added for 6 hrs before luciferase assays.
For over-expression of proteins in MCF-7 cells, the con-
structs (4 μg/6-well) were transfected with Lipofecta-
mine™ 2000. The pCep4b-PrP construct was previously
described [2], and the pCGN-HA-ATF4-IRES-EGFP con-
struct was a kind gift from Dr R. Kaufman [50]. Proteins
were extracted after 24 hrs.
For silencing with siRNAs (at concentrations indicated
above), HEK293 cells were transfected with Lipofecta-
mine™ 2000, MDA-MB-231 and HS578T were trans-
fected with Lipofectamine™ RNAiMAX (Invitrogen), and
MCF-7 cells were transfected by nucleofection (Amaxa Kit
V, VCA-1003, Lonza, Basel, Basel-Stadt, Switzerland) fol-
lowing the manufacturer’s protocol, as these methods
were the best for each specific cell line. The siRNAs
against PrP (siPrP) were human PrP-targeting siRNA from
Santa Cruz Biotechnology (sc-36318) or the Dharmacon
On-TARGETplus human PrP (5621) siRNA. MCF-7 cells
were transfected for 24 hrs before submitting them to an
ER stressor for 18 hrs before RNA or protein extraction.
MDA-MB-231 and HS578T cells were transfected for
24 hrs before RNA or protein extraction.
Chromatin immunoprecipitation assay (ChIP)
The ChIP assays were performed as described previously
[51] with some modifications. MCF-7 cells treated for
three hours with 5 μg/mL BFA or DMSO were harvested
by trypsinization and cross-linked in 1% formaldehyde.
Nuclei were lysed for 20 minutes on ice in sonication
buffer (50 mM Hepes pH 7.4, 140 mM NaCl, 1 mM
EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 1%
SDS, protease inhibitors). Nuclear lysates were sonicated
and pre-cleared with Protein G-Sepharose (Sigma) pre-
coated with 1 μg/mL sonicated salmon sperm nuclei
(Sigma), 1 mg/mL BSA. Chromatin was then incubated
with pre-coated Protein G-Sepharose and ATF6, XBP1
or control IgG antibodies (3 μg). After washing, the
immunoprecipitates were eluted with 50 mM NaHCO3,
1% SDS, 1 mM EDTA and 50 mM Tris-HCl pH 8.0 and
cross-linking reversed. The DNA was purified and used
for PCR amplification.
Cell death assays
For PrP silencing, siRNAs were transfected for 30 minutes,
then ER stress was done for 6 hrs and removed, cell death
assays were conducted after another 18 hrs. For the MCF-
7 cells, 0.1 μg/mL BFA, 1 μg/mL Thps and 5 μg/mL TM
was used. For MDA-MB-231 and HS578T cells, 5 and
10 μg/mL of each ER stressors was used. The chromatin
was stained for 20 minutes with 1 μg/mL Hoechst 33342
(Sigma). Caspase activity was measured with the SR Fluor-
ochrome-labeled inhibitors of caspases (FLICA) poly cas-
pase kit (AbD Serotec, Raleigh, NC, USA) according to the
manufacturer’s instructions.
Molecular mechanism of PrP protection
Prior to seeding, MCF-7 cells were transfected with
scrambled or siPrP by nucleofection (Amaxa Kit V,
VCA-1003, Lonza) following the manufacturer’s protocol.
Cells were treated with ER stressing drugs 5 μg/ml BFA,
1 μg/ml Thps or 5 μg/ml TM for 6 h. Cells were lysed
(150 mM NaCl, 50 mM Tris-HCl pH 8.0, 5 mM EDTA pH
8.0, 1% CHAPS or NP-40, 38 μg/mL AEBSF, 0.5 μg/mL
Pepstatin A, 1 μg/ml TLCK and 0.5 μg/ml Leupeptin) at 6,
12 or 18 h post-treatment and protein content was quanti-
fied using the BCA method. Protein (500 μg) was immuno-
precipitated using Protein G-coupled beads and the active
Bax-specific 6A7 antibody (1:100 or 5 μg/ml, BD Pharmin-
gen, Mississauga, ON, Canada). Beads were washed, resus-
pended in loading buffer, boiled and immunoprecipitated
Bax levels were assessed by Western blot. Lysates were
simultaneously used to investigate BiP, Bax, Bim, Bcl-2 and
b-actin levels by Western blot. Proteins from untransfected
cells lysed in CHAPS or NP-40-containing lysis buffers
acted as negative and positive control for Bax activation.
Statistical analysis
Previously published data and PrP scores in low and high
BiP TMAs were compared with a Student t-test two-way
assuming equal variance. To compare PrP and BiP scores
of each tumor grade, means were compared using non-
parametric Kruskal-Wallis test with the InStat 3.1a software
(GraphPad Software Inc., La Jolla, CA, USA). Correlations
were performed with Spearman’s rank correlation with
InStat. For all other statistical significance tests an analysis
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of variance (ANOVA) followed by Scheffé’s or Tukey-
Kramer post-hoc test was performed using StatView soft-
ware (SAS Institute Inc., Cary, NC, USA). A p-value of less
than 0.05 was taken as a significant difference.
Results
Higher levels of PrP mRNA in breast tumors are
associated with a poor prognosis
Data analyses of three publically available breast cancer
mRNA microarray databases [52-54] revealed that higher
PrP mRNA levels were significantly associated with lower
estrogen (ERS) and progesterone (PR) receptor levels and
higher tumor grades (Table 1). One study indicated an
earlier age of diagnosis in high PrP mRNA tumors [53].
Moreover, a statistically significant association was
observed between high PrP levels and metastatic events
(Table 1). The percentage of individuals with a metastatic
event within five years doubled in the high PrP group and
the number of years that individuals remained lung and
bone metastasis free decreased significantly by one year in
the high PrP group. Analyses of mRNA microarrays of 56
breast carcinoma cell lines [55] showed that basal breast
cancer cell lines have higher PrP mRNA levels than lumi-
nal cell lines (Figure 1). Together, these results indicate
that high PrP mRNA levels are associated with poorer
prognosis breast cancers.
ER stress is associated with increased BiP and PrP levels
in human breast cancer biopsies
To evaluate if ER stress is associated with high PrP
levels, we investigated the ER stress marker BiP (also
known as GRP78) and PrP levels in breast cancer TMA
by immunohistochemistry. PrP was detected in the cyto-
plasm and in the nucleus of epithelial cells, infrequently
found at the cell surface of epithelial cells and was
absent in stromal cells (Figure 2A). On the other hand,
BiP staining was only found in the cytoplasm, as
expected for this ER-resident protein (Figure 2B). Immu-
noreactivity was eliminated in protein-adsorbed antibodies
(Figure 2C, D). The tissue cores were individually analyzed
by a trained pathologist (OA) and scored as 0 (absence of
staining), 1 (mild staining), 2 (moderate staining) and 3
(high staining). PrP immunostaining was only observed in
tumor tissue cores and not in normal tissue cores whereas
BiP was present in both normal and tumor tissue cores
(Figure 2E). Higher PrP and BiP levels segregated with a
higher tumor grade (Figure 2F, G). The high BiP-expres-
sing tumor cores had higher PrP levels than low BiP-
expressing tumors indicating that ER stress is associated
with increased PrP in these tissues (Figure 2H). Further-
more, the levels of PrP correlated significantly with the
loss of estrogen receptor (Spearman r = -0.2036, P =
0.0025) and progesterone receptor (Spearman r = -0.2297,
P = 0.0007) negative tumors (Figure 2I, J). In contrast, no
significant correlation was observed between the levels of
BiP and the estrogen and progesterone receptor status.
Supporting these results, analysis of the mRNA microarray
data [52-54] indicated that in two of three studies, high-
BiP expressing tumors were associated with higher PrP
mRNA levels (Table 2). Furthermore, higher BiP mRNA
in breast carcinoma cell lines correlated with a higher PrP
mRNA level (Table 2). Overall, these results suggest that
ER stress is associated with increased PRNP gene expres-
sion in human breast cancer tumors with a basal subtype
and poor outcome in human patients.
ER stress transcriptionally increases PrP levels in MCF-7 cells
To experimentally assess if ER stressors up-regulate PRNP
gene expression in breast cancer cells, we assessed the
luminal subtype breast carcinoma MCF-7 cell line, which
lacks endogenous PrP expression under steady state condi-
tions. MCF-7 cells were exposed to three different ER
Table 1 Association between PrP mRNA levels and breast cancer parameters













Mean ± SD Mean ± SD P-value Mean ± SD Mean ± SD P-value Mean ± SD Mean ± SD P-value
PrP 0.75 ± 0.1 1.49 ± 0.4 < 0.001* 0.72 ± 0.2 1.53 ± 0.6 < 0.001* 0.63 ± 0.1 1.38 ± 0.4 < 0.001*
ERS 0.81 ± 0.4 0.47 ± 0.5 < 0.001* 0.90 ± 0.3 0.63 ± 0.5 < 0.001* 0.82 ± 0.4 0.33 ± 0.5 < 0.001*
PR 0.68 ± 0.5 0.45 ± 0.5 0.012* Not Available 0.59 ± 0.5 0.27 ± 0.4 0.001*
Grade 2.29 ± 0.7 2.53 ± 0.7 0.049* 2.06 ± 0.8 2.23 ± 0.8 0.068 Not Available
Age 55.1 ± 16 55.1 ± 14 0.995 44.5 ± 5 43.5 ± 6 0.129 58.7 ± 14 53.3 ± 12 0.050*
5Y Met
Event
% with metastasis after 5 yrs 1 = yes, 0 = no 0.19 ± 0.4 0.44 ± 0.5 0.029*
Met Event % with metastatic event independent of time 0.24 ± 0.4 0.42 ± 0.5 0.085
MFS % with metastasis free survival (yrs) 5.63 ± 2.0 4.68 ± 2.5 0.064
LM Event Lung metastasis 0.05 ± 0.2 0.28 ± 0.5 0.007*
LMFS Lung metastasis free survival (yrs) 6.02 ± 1.8 4.96 ± 2.6 0.037*
BM Event Bone metastasis 0.13 ± 0.3 0.21 ± 0.4 0.362
BMFS Bone metastasis free survival (yrs) 5.83 ± 1.9 4.82 ± 2.5 0.046*
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stressors: Golgi-disaggregating BFA, N-linked glycosyla-
tion inhibitor Tunicamycin (TM), and ER Ca-ATPase
family (SERCA) inhibitor Thapsigargin (Thps). Each ER
stressor increased PrP levels in a dose-dependent manner
within 18 hrs of treatment (Figure 3A). PrP accumulated
as immature glycosylated proteins (28 to 33 kDa) with
BFA, as unglycosylated (25 kDa) protein with TM, and as
unglycosylated, immature, and mature (34 to 36 kDa) gly-
cosylated proteins with Thps. Increased BiP protein levels
confirmed induction of the ER stress response with the
BFA, TM and Thps treatments. The ER stress-mediated
up-regulation of PrP appeared specific since serum-depri-
vation of MCF-7 cells for 18 hrs did not increase PrP
levels (Figure 3B). ER stressors increased PrP mRNA levels
within six hours of treatment in MCF-7 cells with conco-
mitant splicing of XBP1 (sXBP1), although sXBP1 was
more prominent in the BFA-treated MCF-7 cells (Figure
3C). ER stress was further confirmed by Western blots
showing an increase of ERP44, GRP94, ERP72 and BiP,
proteins known to be up-regulated in ER stress (Figure
3D). Furthermore, the transcriptional inhibitor actinomy-
cin D (Act D) or the translational inhibitor, cycloheximide
(CHX) strongly inhibited the ER stress-mediated increase
of PrP levels and the increase of the ER stress-related pro-
tein CHOP (Figure 3E). Together, these results show that
ER stress of the luminal breast carcinoma MCF-7 cell line
increases PRNP gene transcription.
PRNP gene expression is up-regulated by ER stress in
basal carcinoma cell lines
A comparison of basal breast carcinoma cell lines,
MDA-MB-231, HS578T and HCC1500, with luminal
MCF-7 cells revealed a high level of PrP in the MDA-
MB-231 and HS578T cell lines but not in the HCC1500
basal cell line. However, BFA, TM and Thps increased
the levels of PrP and BiP in the HCC1500 cell line
(Figure 4B) as observed in the luminal MCF-7 cell line
(Figure 3A). Treatment of MDA-MB-231 and HS578T
cells with 4-phenyl butyric acid (4-PBA), an inhibitor of
ER stress [56], decreases both BiP and PrP levels sug-
gesting that PrP is increased by intrinsic ER stress in
these two basal carcinoma cell lines (Figure 4C). Never-
theless, the three pharmacological ER stressors further
increased both BiP and PrP levels in MDA-MB-231 and
HS578T cells (Figure 4D). Together, these results show
that intrinsic or exogenous ER stress up-regulates PRNP
gene expression in basal breast carcinoma cell lines.
Identification of four ER stress response elements in
PRNP promoter
We identified three potential ER stress response elements
(ERSE) and one ERSE-II motif in the human PRNP pro-
moter using the transcription factor database TRANSFAC
and by manually scanning the PRNP promoter (EMBL
accession no. AJ289875) [48] (Figure 5A). No consensus
UPR element (UPRE) or amino-acid-regulatory element
(AARE) was found in the PRNP promoter. Two ERSE
motifs, named here ERSEa and ERSEb to easily discrimi-
nate between them, were located at nucleotides -89 to -71
and at -20 to -2, respectively. ERSEa was in the opposite
orientation and had a T to A substitution (CCAAT to
CCAAa) compared to the ERSE consensus sequence. The
ERSEb nucleotide sequence also contained two CG substi-
tutions (CCACG to CgACc). One non-conventional ERSE
(ERSE-like) motif, located from -231 to -196 and predicted
by TRANSFAC, contained N26 rather than the canonical
N9 of the glucose-regulated proteins CCAAT-N9-CCACG
ERSE consensus sequence [35]. One canonical ERSE-II
motif was contained within ERSEb (-20 to -10). Compared
to the ERSE-II consensus sequence (ATTGG-N-CCACG),
the ERSE-II motif in the PRNP gene promoter had an A
to C substitution (CCACG to CCcCG).
PRNP transcriptional activation was assessed with the
PRNP promoter-luciferase reporter constructs pGL-214
and pGL-538, which contain 214 or 538 nucleotides
preceding the major transcriptional start site of PRNP,
as well as 125 nucleotides of the non-coding exon I
[48]. Under normal conditions, substantial luciferase
activity was detected in pGL-214- and pGL-538-trans-
fected HEK293T cells, compared to the pGL2 empty
vector-transfected cells (Figure 5B). The three ER stres-
sors increased the luciferase activity in pGL-214- and
pGL-538-transfected cells by 1.7- to 2.6-fold. Point
mutations in the ERSE-like, ERSEa, ERSE-II and ERSEb
motifs (Figure 5C) considerably reduced the constitutive
PRNP promoter activity (Figure 5D). This has also been
observed with other ER stress regulated gene promoters
Figure 1 PrP levels are increased in basal breast carcinoma cell
lines. PrP mRNA levels were averaged in basal or luminal tumor cell
lines. Data represent mean ± SEM of PrP. * indicates p ≤0.05
between both groups.
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Figure 2 PrP levels are significantly higher in high BiP-expressing breast cancer tumors. Representative micrographs of breast tissue cores
immunostained for BiP (C50B12) (A) or PrP (3F4) (B), adsorption control for BiP (C) and PrP (D). E shows staining of PrP and BiP in normal versus
tumor tissue cores. Mean intensity score (mean ± SEM) of PrP (F) or BiP (G) immunostaining correlated with tumor grade. H. Comparison of the
mean intensity score (mean ± SEM) of PrP immunostaining in breast tissue cores showing Low (0 to 1) or High BiP (2 to 3) immunostaining
scores. Correlation between averaged estrogen (I) and progesterone (J) receptor levels in cores (ERS/PR positive = 1 and ERS/PR negative = 0)
correlated with PrP scores. Correlations were done with Spearman’s rank correlation in InStat. ERS versus PrP: r = -0.2036, p = 0.0025, PR vs PrP:
r = -0.2277, P = 0.0007, ERS vs BiP: r = -0.08819, P = 0.2108, and PR vs BiP r = -0.04398, p = 0.5353.
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Table 2 Association between high BiP mRNA levels and PrP mRNA levels
Low BiP High BiP P- n Reference
Mean ± SD Mean ± SD value
BiP 0.80 ± 0.1 1.29 ± 0.3 ≤0.001* 127 van der Vijver et al., 2002
PrP 1.01 ± 0.5 1.24 ± 0.7 0.002*
Breast cancer BiP 0.78 ± 0.1 1.26 ± 0.3 ≤0.001* 44 Minn et al., 2005
PrP 0.93 ± 0.4 1.09 ± 0.5 0.1
BiP 0.76 ± 0.2 1.43 ± 0.4 ≤0.001* 40 Chin et al., 2006
PrP 1.00 ± 0.5 1.38 ± 0.6 0.003*
Breast carcinoma BiP 0.77 ± 0.2 1.37 ± 0.4 ≤0.001* 56 Neve et al., 2006
cell lines PrP 0.99 ± 0.9 1.94 ± 1.0 0.001*
Figure 3 ER stress transcriptionally increases PrP levels in MCF-7 cells. One representative Western blot from at least three independent
experiments is shown in A-B. (A) Western blots of PrP with the 3F4 antibody, BiP, and b-actin in protein extracts from MCF-7 cells treated 18 hrs
with increasing concentrations of Brefeldin A, Tunicamycin, or Thapsigargin. (B) Western blot of PrP (3F4) and b-actin in protein extracts from
MCF-7 cells incubated for 18 hrs in the absence or presence of serum or transfected with pCep4b-PrP (pC-PrP). (C) PrP, XBP1, sXBP1 and b-actin
RT-PCR cDNA amplicons from cells treated for 6 hrs. The ratio of PrP over b-actin was calculated from three independent experiments.
(D) Western blot of various ER stress-regulated proteins in MCF-7 cells treated 18 hrs with BFA, TM or Thps. (E) Western blot of PrP with the 3F4
PrP, CHOP and b-actin antibodies in protein extracts from MCF-7 cells treated 18 hrs with DMSO (Ctl) or ER stressors in the presence or in
absence of cycloheximide (CHX) or actinomycin D (Act D). The immunoreactive band at 37 kDa was not consistently detected with the anti-PrP
3F4 antibody suggesting a non-specific band (ns).
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[35,42,43,57] and may be explained by the presence of
transcriptional motifs overlapping the ERSE as indicated
in Figure 4C. Alternatively, the mutations affect the
structure of the promoter rendering it less responsive to
transcriptional factors. Cells treated with BFA lost their
ability to significantly induce luciferase activity in the
PRNP ERSE mutants (Figure 5E). The ERSE-like and
ERSEb mutations abolished the induction of luciferase
activity in Thps-treated cells, while it was retained in
the ERSEa and ERSE-II mutants. TM induced luciferase
activity in the cells transfected with wild type or mutant
ERSE-like, ERSEa and ERSEb PRNP promoter but not in
the ERSE-II mutant. The four ERSE motifs of the
human PRNP promoter are well conserved among pri-
mates (Figure 5F), but not well conserved in other
mammalian species. Only the ERSE-like is highly con-
served in the mouse, rat or hamster Prnp promoters.
Taken together, these results indicate that (a) the PRNP
promoter ERSE motif sequences overlap with those regu-
lating the basal expression of PRNP, (b) the ERSE motifs
positively regulate ER stress-mediated transcription of
the PRNP gene, (c) the PRNP promoter is differentially
regulated with the three different ER stresses, and (d) ER
stress-mediated regulation of PRNP gene expression may
have evolved in primates but not in other mammalian
species.
Role of ATF6a and XBP1 in ER stress-mediated PRNP
gene expression
To determine which transcription factor regulates ER
stress-mediated PRNP gene expression in MCF-7 cells, we
investigated ΔATF6a, sXBP1 and phosphorylation of
eIF2a (peIF2a), as markers of the three UPR response
pathways, and compared these to PrP levels. Because the
ATF4 motif is absent in the PRNP promoter, we focused
on ΔATF6a and sXBP1. In MCF-7 cells, ΔATF6a and
peIF2a appeared within 30 minutes, sXBP1 increased
between one to two hours, and PrP levels increased within
one hour of BFA treatment (Figure 6A). With Thps, trun-
cated ATF6a increased at three hours, peIF2a and sXBP1
increased within 30 minutes, and PrP levels increased at
six hours of treatment. TM induced truncated ATF6a
Figure 4 ER stress increases PrP levels in MDA-MB-231, HS578T and HCC1500 cell lines. Western blot of (A) PrP in protein extracts of
MCF-7, MDA-MB-231, HS578T and HCC1500 cell lines, (B) PrP and BiP in protein extracts from HCC1500 cells treated with BFA, TM or Thps,
(C) PrP and BiP in protein extracts from MCF-7, MDA-MB-231 and HS578T cell lines treated with 4-PBA or vehicle, (D) PrP and BiP in protein
extracts of MDA-MB-231 and HS578T cell lines treated with BFA, TM and Thps. b-actin was probed as a loading control.
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Figure 5 Identification of ER stress response elements (ERSE) in the PRNP promoter. (A) Schematic diagram of two ERSE (ERSEa and
ERSEb), one ERSE-like, and one ERSE-II in the human PRNP promoter. (B) Luciferase activity in HEK293T cells transfected with pGL2 (empty
vector), pGL-214 (vector containing the first 214 nucleotides of human PRNP promoter), or pGL-538 (first 538 nucleotides of human PRNP
promoter) and treated six hours with ER stressors. Data are expressed as the mean ± SD of two experiments done in triplicate. * Indicates P
≤0.05 compared to the control (Ctl). (C) Schematic diagram of the PRNP promoter mutants showing the mutated nucleotides in bold. Putative
transcription factor binding sites predicted by TRANSFAC and the conserved motif 4 affected by the mutations are shown. (D) Luciferase activity
measured in HEK293T cells transfected with wild type PRNP promoter (pGL-538) or ERSE mutants of the PRNP promoter. Data represent the
mean ± SEM of three experiments done in triplicate. * Indicates P ≤0.05 compared to wild type. (E) Luciferase activity in HEK293T cells
transfected with wild type or ERSE mutant PRNP promoters and treated with DMSO (control) or ER stressors. The fold increase of luciferase
activity calculated for each PRNP promoter construct corresponds to the ratio of the RLU in presence of ER stress over the RLU in presence of
DMSO (Control). Data represent the mean ± SEM of three independent experiments done in triplicate. * Indicates P ≤0.05 compared to the
control (DMSO) and # indicates P ≤0.05 between the mutants and the wild type PRNP promoter. (F) Schematic diagram showing conservation of
human ERSE-like, ERSEa, ERSE-II and ERSEb. Nucleotide sequence alignment of PRNP promoters is from a previous study [48] and from an
alignment done with Ensembl databases. N indicates the number of nucleotide. Compared to human PRNP promoter, * indicates a non-
conserved and non-complementary nucleotide while X denotes an absent nucleotide.
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Figure 6 sXBP1 is involved in PRNP gene expression in MCF-7 and MDA-MB-231 cells. (A) Western blot analyses of PrP with the 3F4
antibody, cleaved ATF6a (ΔATF6a), phosphorylated eIF2a (peIF2a), total eIF2a, and b-actin. Lower panels represent XBP1, spliced XBP1 (sXBP1)
and b-actin amplified by RT-PCR. Protein or mRNA extracts were from MCF-7 cells treated with ER stressors for 0 to 6 hrs. The increase of PrP
and ΔATF6a levels compared to b-actin levels and the ratios of peIF2a/eIF2a and sXBP1/XBP1 are indicated. (B) MCF-7 cells transfected with
siATF6a or siXBP1 and proteins immunoblotted with 3F4 PrP and b-actin antibodies. RT-PCR shows levels of ATF6a and XBP1 mRNAs.
(C) Western blot analyses of PrP, HA tag and b-actin in protein extracts from MCF-7 cells transfected for 6 hrs with pCGN-IRES-EGFP (Ctl), pCGN-
HA-sXBP1-IRES-EGFP, and pCGN-HA-ATF4-IRES-EGFP constructs. (D) ChIP assays performed on DMSO (Ctl)- or BFA-treated MCF-7 cells with IgG
control, XBP1 or ATF6a antibodies. PCR amplification of PRNP and b-actin gene promoters (ACTB) was done on immunoprecipitated and non-
immunoprecipitated (input) DNA. (E) Western blot of PrP (top panel) and b-actin (bottom panel) and ethidium stained agarose gel containing
ATF6a and XBP1 amplicons from MDA-MB-231 or HS578T cells transfected with siCtl, siATF6a or siXBP1. NT indicates non-transfected, D
indicates the Dharmacon siRNAs and SC indicates the Santa Cruz siRNAs. (F) Levels of PRNP mRNA detected by qRT-PCR in siATF6a or siXBP1-
transfected cells.
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within one hour, peIF2a within three hours, and sXBP1
and PrP within two to three hours. Variation in total
eIF2a levels was observed under the three ER stressors, as
previously reported [58,59], while b-actin mRNA and pro-
tein levels remained relatively constant. These results indi-
cate that all three UPR response pathways are activated
before ER stress-mediated PrP up-regulation in MCF-7
cells.
Silencing ATF6a with two different siRNAs did not
alter TM-mediated increased levels of PrP (Figure 6B).
However, knock down (KD) of XBP1 in MCF-7 cells,
considerably stunted the TM-mediated increase in PrP.
Over-expression of HA-tagged sXBP1 increased PrP
levels above low levels observed in cells transfected with
the control pCGN-IRES-EGFP vector, while HA-tagged
ATF4 did not modulate PrP levels (Figure 6C). Using
chromatin immunoprecipitation (ChIP) assays, we
further showed that both XBP1 and ATF6a bound to the
PRNP promoter in BFA-treated MCF-7 cells (Figure 6D).
In contrast, neither interacted with the b-actin ACTB
promoter. These results show that sXBP1 in MCF-7 cells
is involved in transactivating PRNP gene expression,
whereas ATF6a can interact with, but does not transacti-
vate PRNP.
To determine if PRNP gene expression in the basal car-
cinoma cell lines depends on ER stress, we knocked down
(KD) ATF6a and XBP1 with siRNAs in the MDA-MB-231
and HS578T cell lines (Figure 6E). In the MDA-MB-231
cell line, two different siRNAs to ATF6a and XBP1 effi-
ciently decreased the levels of ATF6a and sXBP1, respec-
tively (Figure 6E). The level of PrP (Figure 6E) and PRNP
mRNA (Figure 6F) were not decreased by the ATF6a KD.
However, the siCtl and siATF6a produced an unexpected
increase in sXBP1 in MDA-MB-231 cells, which could
obscure the effect of siATF6a on PRNP gene expression.
Indeed, an almost complete XBP1 KD with siXBP1 SC
decreased PrP and PRNP mRNA levels by 40%, whereas a
partial siXBP1 D KD did not decrease PRNP gene expres-
sion at either the protein or mRNA level (Figure 6E, F).
Both pairs of siRNAs against ATF6a and XBP1 were
highly efficient in the HS578T cell line and the siCtl
or siATF6a had much less effect on the levels of sXBP1
(Figure 6E). The levels of PrP assessed by Western blotting
decreased relative to the non-transfected cells but not
necessarily relative to the siCtl, except for the siATF6a SC
(Figure 6E). Furthermore, qRT-PCR results showed that
the levels of PrP mRNA decreased by 40% only with the
siXBP1 SC (Figure 6F). The discrepancy between the effect
of these two different siXBP1s is unclear. Both decrease
XBP1 mRNA levels similarly so we must assume that one
of these has off-target effects that differentially regulate
PRNP gene expression. These results indicate that the
ATF6a is not regulating PRNP gene expression in MDA-
MB-231 or HS578T cell lines, while XBP1 is possibly
implicated in the MDA-MB-231 cell line.
sXBP1 and ΔATF6a regulate luciferase activity from the
pGL-538 PRNP promoter in HEK293 cells
To more directly assess if sXBP1 and ΔATF6a transactivate
PRNP gene expression from its promoter, HEK293 cells
were co-transfected with pCGN constructs encoding sXBP1
or ΔATF6a and the pGL-538 PRNP promoter luciferase
reporter construct. Overexpression of both ΔATF6a and
sXBP1 was confirmed by RT-PCR (Figure 7A) and both of
these transcription factors transactivated luciferase expres-
sion from the pGL-538 PRNP promoter luciferase reporter
construct (Figure 7B). Furthermore, KD of ATF6a and
XBP1 expression with two different siRNAs (Figure 7C),
prevented Thps-induced luciferase expression from the
pGL-538 construct (Figure 7D). The siATF6a SC siRNA
induced an overall increase in luciferase activity compared
to the siCtl but the levels did not differ between DMSO and
Thps. This suggests that this siRNA may induce other tran-
scription factors that up-regulate PRNP gene expression.
Taken together, these results confirm that both ATF6a and
sXBP1 can up-regulate PRNP gene expression in HEK293
cells.
PrP delays ER stress-mediated cell death
One way PrP could favor cancer progression is by oppos-
ing cell death. Because the cellular form of PrP has anti-
apoptotic activity, we investigated if PrP up-regulation
could participate in the UPR pro-survival response.
Compared to control siRNA, PrP silencing increased
the percentage of cells displaying pan-caspase activity
(Figure 8A) and condensed chromatin (Figure 8B) in
MCF-7 cells treated with BFA, Thps or TM. A similar
vulnerability against ER stressors was observed in hippo-
campal Prnp null cells (Figure 8C, E). Furthermore,
siRNA KD of PrP increased the levels of pan-caspase
activity in MDA-MB-231 cells treated with the three ER
stressors, indicating a protection by PrP in this basal cell
line (Figure 8E). However, we did not observe higher cas-
pase activity in the HS578T cell line, except in the 10 μg/ml
Thps condition (Figure 8F). This result indicates that differ-
ent cell lines require different doses of ER stress for induc-
tion of cell death. Nevertheless, the results indicate that
PrP delays ER stress-induced cell death in MCF-7 and in
MDA-MB-231 cells.
PrP does not prevent ER stress-mediated Bax activation
in MCF-7 cells
We have previously discovered that PrP can inhibit Bax-
mediated cell death [2,4]. Immunoprecipitation of the
pro-apoptotic 6A7-immunoreactive form of Bax indi-
cated that BFA, TM and Thps all induce Bax activation
Déry et al. Breast Cancer Research 2013, 15:R22
http://breast-cancer-research.com/content/15/2/R22
Page 12 of 19
(Figure 9A-C). However, silencing PrP before ER stress
did not increase the level of Bax activation indicating
that PrP cannot prevent ER stress-induced Bax activa-
tion and that PrP delays ER stress-mediated cell death
by another mechanism.
ER stress with BFA, TM or Thps was confirmed by
up-regulation of BiP levels in the presence or absence of
PrP KD (Figure 9A-C). ER stress is known to induce
CHOP during apoptosis and CHOP transcriptionally
increases pro-apoptotic protein, Bim [60]. Bim was
increased in Thps-treated MCF-7 cells (Figure 9C), but
not in BFA or TM-treated cells (Figure 9A, B). Again,
siRNA inhibition of ER stress-mediated PrP gene
expression did not alter Bim levels. Bcl-2 levels were
also constant in ER stress-treated cells with or without
PrP silencing with siRNAs. We repeated these experi-
ments with another siRNA against PrP and observed
identical results (Figure 9D). Therefore, it is unlikely
Figure 7 ATF6a and XBP1 transactivate PRNP promoter. (A) Ethidium bromide stained gel showing ΔATF6a, sXBP1 and XBP1 amplicons
from HEK293 cells co-transfected with the pGL-538 PRNP promoter luciferase reporter and pCGN-ATF6a (1-373) and/or pCGN-sXBP1.
(B) Luciferase luminescence generated from HEK293 cells co-transfected as described in A. (C) Ethidium bromide stained gel showing ATF6a and
XBP1 amplicons from HEK293 cells co-transfected with the pGL-538 PRNP promoter luciferase reporter and siRNAs against ATF6a or XBP1.
(D) Luciferase luminescence generated from HEK293 cells co-transfected as described in C. Statistical analyses on B and D were one-way ANOVA
followed by a Tukey-Kramer multiple comparison test.
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Figure 8 PrP delays cell death induced by ER stress. (A) inset shows western blot of PrP and b-actin in siRNA transfected cells. Percentage of
cell death assessed by pan-caspase FLICA (A) or by chromatin condensation (B) in MCF-7 cells transfected with control (siCtl) or PrP (siPrP)
siRNAs for 24 hrs and treated with ER stressors or DMSO (control) during 6 hrs. Cell death was measured 18 hrs after the removal of ER stress.
Data represent the mean ± SEM of three (A) or six (B) independent experiments. At least 150 cells were counted per experiment. * Indicates P ≤
0.05 between PrP siRNA and control siRNA. (C-D) Percentage of cell death assessed by FLICA staining for active caspases (C) or by chromatin
condensation in PrP+/+ and PrP-/- hippocampal cell lines (D). Data represent the mean ± SEM of four independent experiments. At least 150
cells were counted per experiment. * Indicates P ≤0.05 between PrP+/+ and PrP-/- cells. C Inset: Western blot analysis of PrP with the R155
antibody and b-actin in protein extracts from mouse PrP+/+ and PrP-/- hippocampal cell lines. PrP-/- hippocampal cell lines were treated with
2.5 μg/ml of ER stressors. These concentrations were empirically determined to induce ER stress response without initially inducing strong toxic
effects. (E) Relative fluorescence units (RFU) of FLICA activity representing pan-caspase activity in MDA-MB-231 (E) or HS578T (F) cells transfected
with siCtl or siPrP.
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that PrP protects against ER-mediated cell death by tar-
geting members of the Bcl-2 family of proteins.
Discussion
In the present manuscript, we show that (1) human
PRNP gene expression is up-regulated by ER stress, (2)
that the UPR-activated sXBP1 and ΔATF6a are involved
in transcriptional activation of PRNP, (3) that PrP pro-
tects against ER stress-mediated cell death, and (4) that
PrP may contribute to increased survival of breast
cancers.
Our first observation in this study was that PRNP gene
expression is regulated by ER stress in both basal and
luminal breast cancer cell lines. Indeed, three different ER
Figure 9 PrP does not prevent ER stress-mediated Bax activation in MCF-7 cells. Western blot assessing the impact of PrP silencing on Bax
activation as well as Bim and Bcl-2 levels at 6, 12 or 18 h following a 6-h treatment with Brefeldin A (A), Tunicamycin (B), or Thapsigargin (C).
Western blot using the 3F4 antibody confirms ER stress-induced increase in PrP levels as well as its efficient siRNA-mediated silencing, while
probing for Bax and b-actin controls for equal protein input and protein loading, respectively. (D) MCF-7 cells transfected with a second siPrP
and treated for 18 h with ER stressor; experiments performed as described in A-C.
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stressors increase the levels of PrP in MCF-7 cells and in
the MDA-MB-231, HS578T and HCC1500 breast carci-
noma cell lines. The MDA-MB-231 and HS578T cell lines
have intrinsic ER stress activity based on higher levels of
ER stress-regulated BiP and correspondingly have much
higher PrP levels than the MCF-7 and HCC1500 cell lines.
Furthermore, the ER stress inhibitor, 4-PBA, decreases
both BiP and PrP in MDA-MB-231 and HS578T cell lines.
While the overexpression of PrP definitely has a negative
impact on several types of cancers, surprisingly little is
known about the regulation of PRNP gene expression.
Human PRNP is localized on chromosome 20 and con-
tains a short un-translated exon I separated from the cod-
ing exon II by a 13 kb intron [48,61-63]. PRNP has one
major transcriptional start site and its promoter contains a
CCAAT box, a high G/C content, and an SP1 transcrip-
tion factor binding site characteristic of constitutively
expressed genes. It also contains several putative condi-
tionally activated transcriptional binding sites: develop-
mentally-regulated GATA, AP-2, Nkx2-5 and Myo D,
signal-dependent p53 and HSE, cell membrane receptor-
dependent AP1, immune-mediated nuclear factor IL-6,
NF-AT and Ets-1, and metal responsive element binding
sites [48,62,64]. These transcriptional binding site
sequences are located in two clusters, one within exon I,
and the other in the 800 nucleotides upstream of the start
site. Of these, only Sp1, metal transcription factor-1
(MTF-1), HSE and p53 recently have been confirmed to
regulate human PRNP or mouse Prnp gene expression
[21,64-66]. In addition, four motifs with unknown function
are highly conserved among mammalian PRNP promoters
[48,67]. Our finding that ER stress can up-regulate PRNP
gene expression has certain implications in cancer because
cancers are ER stressed [68] and PrP has been reported to
have protective functions that appear to be involved in the
resistance of cancers to chemotherapy [12-14,69].
Our second observation is that the up-regulation of PrP
occurs through transactivation of the PRNP gene. We
describe four ERSE in the promoter of PRNP, which
respond to the three pharmacological ER stressors, BFA,
Thps and TM. Mutagenesis of these ERSE dampens the
ER stress-mediated up-regulation of PRNP. In addition,
ΔATF6a and sXBP1 directly increase expression from the
PRNP promoter and siRNAs against either ATF6a or
XBP1 prevents Thps-mediated PRNP gene expression.
Furthermore, ChIP analyses shows that both XBP1 and
ATF6a interact with the PRNP promoter. In MCF-7 cells,
the three pharmacological ER stressors increase ATF6a
and sXBP1 but only the KD of XBP1 prevents ER stress-
mediated up-regulation of PRNP gene expression. A simi-
lar effect is observed in MDA-MB-231 cells but not in the
HS578T cell line. These results suggest that PRNP gene
expression can be regulated by both ATF6a and XBP1,
but that the regulation is complex and depends on the
cellular context. Together, these results add ER stress as
an important human regulator of PRNP gene expression.
Interestingly, the ERSE elements are specific to primate
PRNP promoters since three of the ERSE elements are
quite degenerate in rodents and ovines while the remain-
ing ERSE is conserved in rodents but not in ovines. In
addition, PRNP gene expression is differentially regulated
by each of the three ER stressors. The presence of these
ERSE in the primate PRNP promoter and the differential
regulation by ER stressors suggests that the regulation of
PRNP gene expression is highly complex in primates and
is consistent with the reported inability of ER stress to
increase PrP levels in murine cells [70-72]. It must, there-
fore, be noted that ER stress regulation of Prnp gene
expression would remain undetected in mouse models of
disease.
Our third finding is that increased ER stress-mediated
prnp gene expression protects cells from ER stress-
mediated cell death. This is shown by KD of PrP in MCF-
7 and MDA-MB-231 cells and in PrP null hippocampal
cell lines. However, PrP does not protect HS578T cells
from ER stress mediated cell death. These results indicate
that the protective function of PrP may not be universal to
breast carcinoma cells and that other pathways are
involved. This is not unexpected given the complexity of
cancers. Previous studies have shown that KD of PrP
restores the susceptibility of TRAIL resistant MCF-7 cell
lines [12] and over-expression of PrP induces MCF-7
resistance to TNF-a-mediated cell death [13]. These
results are entirely consistent with the previously reported
protective role of PrP in MCF-7 cells [4,12,13].
However, the mechanism by which PrP protects against
ER stress is unclear here. We had previously shown that
PrP could prevent Bax-mediated cell death in MCF-7
cells and in human primary neurons [2,3], by preventing
the conversion of Bax to pro-apoptotic Bax [4]. However,
while we observe the activation of Bax with ER stress in
these experiments, silencing PrP does not increase levels
of Bax activation. Others have reported ER stress protec-
tive mechanisms against estrogen-deprived breast cancer
cell death. One of the proposed mechanisms involves BiP
directly. Zhou and colleagues identified that BiP protects
MCF-7/BUS-10 estrogen starvation resistant cells by
interacting with the BH3 domain pro-apoptotic protein
Bik, thus allowing the release of Bcl-2 from Bik and
increased survival via inhibition of Bax [73]. Other stu-
dies show that BiP can regulate cell death via both cas-
pase-dependent and independent cell death [74], and that
IGFBP-3 acts as a survival factor in the HS578T cell line
via BiP and autophagy [75,76]. However, we show that
PrP KD, while increasing protection against ER stress in
MCF-7 cells, does not alter the levels of BiP. Therefore,
we can exclude BiP as a direct regulator of survival
through PrP. Together these results suggest that multiple
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protective pathways are involved in increasing breast can-
cer cell resistance to cell death.
Lastly, we describe that the ER stress-mediated increase
in PrP levels is associated with increased cellular survival
in human breast cancers. Our TMA analyses of human
breast carcinomas showed that (a) high ER stress marker
BiP levels were associated with higher PrP levels, (b) both
BiP and PrP levels were higher in grade 3 tumors com-
pared to grade 1 tumors, and (c) levels of PrP correlate
with estrogen and progesterone receptor negative tumors.
In three independent mRNA microarray analyses [52-54],
higher levels of PrP mRNA were significantly associated
with estrogen receptor negative cancers consistent with
the previously reported higher resistance to adjuvant che-
motherapy in estrogen receptor negative and PrP positive
cancers [14]. Additionally, (a) two of the microarray ana-
lyses showed a significant reduction of progesterone
receptor levels in high PrP expressing cancers [53,54], (b)
one study showed a significant association of high PrP
mRNA levels with tumor grade [54], and (c) one study
showed a lower age at diagnostic [53] and an increase in
metastatic events in high PrP mRNA tumors [53]. Further-
more, microarrays show that increased PrP mRNA levels
are associated with ER stress in the most aggressive basal
breast carcinoma cell lines compared with the less aggres-
sive luminal cell lines ([55] and Figure 1). These results
are consistent with findings that estrogen receptor positive
breast cancers that are resistant to tamoxifen were shown
to have increased sXBP1, indicating that increased ER
stress conditions promote survival of luminal cancers [68].
These results indicate that higher PrP levels are associated
with a poor outcome in breast cancer.
Conclusions
Together, these results indicate that ER stress increases
levels of PrP that contribute to cell survival in some breast
cancer cell lines. These results establish PRNP as a novel
clinically relevant ER stress-regulated gene that may be
implicated in increased survival of breast cancer tumor
cells. Therefore, targeting the ER stress response and PrP
may help in the treatment of a category of breast cancer
tumors that are resistant to conventional treatments.
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